<iati-activities>
 <iati-activity default-currency="CAD" dstore:dataset="idrccrdi-act2" dstore:index="2075" iati-activities:generated-datetime="2016-10-03T20:12:22" iati-activities:version="2.01" last-updated-datetime="2016-04-07T00:00:00" xml:lang="EN" xmlns:dstore="http://d-portal.org/xmlns/dstore" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <activity-date iso-date="2015-03-26" type="2"></activity-date>
  <activity-date iso-date="2017-04-26" type="3"></activity-date>
  <activity-scope code="3"></activity-scope>
  <activity-status code="2"></activity-status>
  <collaboration-type code="1"></collaboration-type>
  <conditions attached="1">
   <condition type="2">
    <narrative xml:lang="EN">Grant is conditional on completion of specified terms of reference, receipt of specified deliverables</narrative>
    <narrative xml:lang="FR">La bourse est octroy&#xE9;e &#xE0; condition de respecter le mandat &#xE9;tabli et de livrer les r&#xE9;sultats attendus</narrative>
   </condition>
   <condition type="3">
    <narrative xml:lang="EN">Grant is conditional on periodic submission of a detailed accounting of expenditure of funds received from IDRC accompanied by estimation of budget for the next reporting period</narrative>
    <narrative xml:lang="FR">La bourse est octroy&#xE9;e &#xE0; condition de p&#xE9;riodiquement pr&#xE9;senter une justification d&#xE9;taill&#xE9;e de l&apos;utilisation des fonds vers&#xE9;s par le CRDI ainsi qu&apos;une estimation budg&#xE9;taire de la p&#xE9;riode de rapport suivante</narrative>
   </condition>
  </conditions>
  <contact-info type="1">
   <email>info@idrc.ca</email>
   <mailing-address>
    <narrative xml:lang="EN">PO Box 8500, Ottawa ON Canada, K1G 3H9</narrative>
    <narrative xml:lang="FR">CP 8500, Ottawa ON Canada, K1G 3H9</narrative>
   </mailing-address>
   <organisation>
    <narrative xml:lang="EN">International Development Research Centre</narrative>
    <narrative xml:lang="FR">Centre de recherches pour le d&#xE9;veloppement international</narrative>
   </organisation>
   <telephone>(+1) 613-236-6163</telephone>
   <website>http://www.idrc.ca</website>
  </contact-info>
  <country-budget-items vocabulary="1"></country-budget-items>
  <crs-add>
   <loan-status currency="CAD"></loan-status>
  </crs-add>
  <default-aid-type code="D01" vocabulary="1"></default-aid-type>
  <default-finance-type code="110"></default-finance-type>
  <default-flow-type code="10"></default-flow-type>
  <default-tied-status code="5"></default-tied-status>
  <description type="1">
   <narrative xml:lang="EN">This initiative supports phases 2 and 3 clinical trials of an experimental Ebola vaccine. The experimental vaccine is based on an attenuated recombinant Vesicular Stomatitis Virus vector (VSV-EBOV). The Public Health Agency of Canada developed the vaccine and licensed it to NewLink Genetics and Merck. 

Early vaccine trials
During the multicentre phase 1 trials, researchers demonstrated the vaccine&apos;s safety and its ability to provoke an immune response (immunogenicity). The next trials will determine the expanded safety, protective immune response, and efficacy of the vaccine with at-risk populations in Africa. 

The trials will allow African teams to strengthen their clinical research capacities. The initiative is supported through a partnership of Foreign Affairs, Trade and Development Canada, the Canadian Institutes of Health Research, IDRC, and the Public Health Agency of Canada.

Phases 2 and 3 clinical trials
The phase 3 clinical trial of the VSV-EBOV vaccine will take place in Guinea, one of the main Ebola-affected countries in West Africa. An international research consortium headed by the Norwegian Institute of Public Health is leading the trials. The World Health Organization is coordinating the consortium. 

The clinical trial will determine the safety, protective immune response, and efficacy of the vaccine to prevent infection and the spread of the disease. Working with colleagues from Mali and Senegal, Canada will provide support for field monitoring, trial assessment, and developing Guinean clinical research capacities. The Centre hospitalier universitaire Sainte-Justine will host and chair the Data Safety Monitoring Board, an essential validating and transparency function for the vaccine trials. Canada will co-chair the Scientific Advisory Group for the Guinea Ebola vaccine trials.

The partnership is discussing support for additional phase 2 clinical trials of the VSV-EBOV vaccine. These would take place in Canada and one at-risk African country not affected by the current epidemic. These trials would be performed in partnership with other donors. This will help create strong evidence of the vaccine&apos;s safety and protective immune response in broader populations, including children and HIV-positive people.

Results from the project activities will be shared with the international community as part of the global response to the Ebola crisis. The results will inform the approval of the VSV-EBOV vaccine for future use to prevent Ebola transmission.</narrative>
   <narrative xml:lang="FR">Cette initiative soutient les essais cliniques de phases II et III d&apos;un vaccin exp&#xE9;rimental contre le virus Ebola. Le vaccin exp&#xE9;rimental se base sur un vecteur du virus de la stomatite v&#xE9;siculaire (VSV-EBOV) recombinant att&#xE9;nu&#xE9;. L&apos;Agence de la sant&#xE9; publique du Canada a mis au point le vaccin et l&apos;a homologu&#xE9; pour NewLink Genetics et Merck. 

Essais initiaux de vaccins
Au cours des essais multicentriques de phase I, les chercheurs ont d&#xE9;montr&#xE9; l&apos;innocuit&#xE9; du vaccin et sa capacit&#xE9; &#xE0; provoquer une r&#xE9;ponse immunitaire (immunog&#xE9;nicit&#xE9;). Les essais suivants d&#xE9;termineront l&apos;innocuit&#xE9; &#xE9;largie, la r&#xE9;ponse immunitaire protectrice et l&apos;efficacit&#xE9; du vaccin au sein des populations &#xE0; risque en Afrique. 

Les essais permettront aux &#xE9;quipes africaines de renforcer leurs capacit&#xE9;s de recherche clinique. L&apos;initiative est financ&#xE9;e par l&apos;interm&#xE9;diaire d&apos;un partenariat entre Affaires &#xE9;trang&#xE8;res, Commerce et D&#xE9;veloppement Canada, les Instituts de recherche en sant&#xE9; du Canada, le CRDI et l&apos;Agence de la sant&#xE9; publique du Canada.

Essais cliniques de phases II et III
L&apos;essai clinique de phase III du vaccin VSV-EBOV aura lieu en Guin&#xE9;e, l&apos;un des pays d&apos;Afrique de l&apos;Ouest les plus durement touch&#xE9;s par le virus Ebola. Un consortium de recherche international dirig&#xE9; par le Norwegian Institute of Public Health dirige les essais. L&apos;Organisation mondiale de la sant&#xE9; coordonne le consortium. 

L&apos;essai clinique d&#xE9;terminera l&apos;innocuit&#xE9;, la r&#xE9;ponse immunitaire protectrice et l&apos;efficacit&#xE9; du vaccin pour pr&#xE9;venir l&apos;infection et la propagation de la maladie. En travaillant avec des coll&#xE8;gues du Mali et du S&#xE9;n&#xE9;gal, le Canada apportera son soutien pour la surveillance sur le terrain, l&apos;&#xE9;valuation des essais et le renforcement des capacit&#xE9;s de recherche clinique en Guin&#xE9;e. Le Centre hospitalier universitaire Sainte-Justine pr&#xE9;sidera le Comit&#xE9; de surveillance des donn&#xE9;es relatives &#xE0; l&apos;innocuit&#xE9;, une fonction essentielle de validation et de transparence pour les essais du vaccin. Le Canada copr&#xE9;sidera le Groupe consultatif scientifique pour les essais du vaccin contre le virus Ebola en Guin&#xE9;e.

Le partenariat discute du soutien &#xE0; apporter aux essais cliniques de phase II suppl&#xE9;mentaires du vaccin VSV-EBOV. Ces essais auraient lieu au Canada et dans un pays africain &#xE0; risque non touch&#xE9; par l&apos;&#xE9;pid&#xE9;mie actuelle. Ils seraient r&#xE9;alis&#xE9;s en partenariat avec d&apos;autres bailleurs de fonds. Cela permettra de cr&#xE9;er de solides donn&#xE9;es probantes sur l&apos;innocuit&#xE9; du vaccin et la r&#xE9;ponse immunitaire protectrice chez des populations plus vastes, y compris les enfants et les personnes s&#xE9;ropositives.

On transmettra les r&#xE9;sultats issus des activit&#xE9;s du projet &#xE0; la communaut&#xE9; internationale dans le cadre de la r&#xE9;ponse mondiale &#xE0; la crise du virus Ebola. Ces r&#xE9;sultats guideront l&apos;approbation du vaccin VSV-EBOV aux fins d&apos;utilisation future pour pr&#xE9;venir la transmission du virus Ebola.</narrative>
  </description>
  <iati-identifier>XM-DAC-301-2-108016-004</iati-identifier>
  <participating-org role="1" type="10">
   <narrative xml:lang="EN">Canada. Parliament</narrative>
   <narrative xml:lang="FR">Canada. Parlement</narrative>
  </participating-org>
  <participating-org role="1" type="10">
   <narrative xml:lang="EN">Canada. Global Affairs Canada</narrative>
   <narrative xml:lang="FR">Canada. Affaires mondiales Canada</narrative>
  </participating-org>
  <participating-org role="4" type="15">
   <narrative xml:lang="EN">International Development Research Centre</narrative>
   <narrative xml:lang="FR">Centre de recherches pour le d&#xE9;veloppement international</narrative>
   <narrative xml:lang="ES">Centro Internacional de Investigaciones para el Desarrollo</narrative>
  </participating-org>
  <participating-org role="3" type="15">
   <narrative xml:lang="EN">International Development Research Centre</narrative>
   <narrative xml:lang="FR">Centre de recherches pour le d&#xE9;veloppement international</narrative>
   <narrative xml:lang="ES">Centro Internacional de Investigaciones para el Desarrollo</narrative>
  </participating-org>
  <participating-org role="2" type="15">
   <narrative xml:lang="EN">International Development Research Centre</narrative>
   <narrative xml:lang="FR">Centre de recherches pour le d&#xE9;veloppement international</narrative>
   <narrative xml:lang="ES">Centro Internacional de Investigaciones para el Desarrollo</narrative>
  </participating-org>
  <policy-marker code="1" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="2" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="3" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="5" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="4" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="6" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="7" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="8" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="9" significance="0" vocabulary="1"></policy-marker>
  <policy-marker code="104" significance="1" vocabulary="99"></policy-marker>
  <policy-marker code="101" significance="2" vocabulary="99"></policy-marker>
  <policy-marker code="102" significance="0" vocabulary="99"></policy-marker>
  <policy-marker code="103" significance="0" vocabulary="99"></policy-marker>
  <recipient-region code="X7" percentage="100" vocabulary="1"></recipient-region>
  <reporting-org ref="XM-DAC-301-2" type="15">
   <narrative xml:lang="EN">International Development Research Centre</narrative>
   <narrative xml:lang="FR">Centre de recherches pour le d&#xE9;veloppement international</narrative>
   <narrative xml:lang="ES">Centro Internacional de Investigaciones para el Desarrollo</narrative>
  </reporting-org>
  <sector code="12250" percentage="100" vocabulary="1"></sector>
  <sector code="00001" percentage="100" vocabulary="99">
   <narrative xml:lang="EN">Other</narrative>
   <narrative xml:lang="FR">Autre</narrative>
  </sector>
  <title>
   <narrative xml:lang="EN">Clinical Trials of an Experimental Ebola Vaccine: A Canadian Research Response</narrative>
   <narrative xml:lang="FR">Essais cliniques d&apos;un vaccin exp&#xE9;rimental contre le virus Ebola : une intervention canadienne dans la recherche</narrative>
  </title>
  <transaction>
   <disbursement-channel code="2"></disbursement-channel>
   <provider-org>
    <narrative xml:lang="EN">Canada. Parliament</narrative>
    <narrative xml:lang="FR">Canada. Parlement</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">International Development Research Centre</narrative>
    <narrative xml:lang="FR">Centre de recherches pour le d&#xE9;veloppement international</narrative>
    <narrative xml:lang="ES">Centro Internacional de Investigaciones para el Desarrollo</narrative>
   </receiver-org>
   <recipient-region vocabulary="1"></recipient-region>
   <transaction-date iso-date="2016-03-31"></transaction-date>
   <transaction-type code="2"></transaction-type>
   <value currency="CAD" value-date="2016-03-31">
   </value>
  </transaction>
  <transaction>
   <disbursement-channel code="2"></disbursement-channel>
   <provider-org>
    <narrative xml:lang="EN">Canada. Global Affairs Canada</narrative>
    <narrative xml:lang="FR">Canada. Affaires mondiales Canada</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">International Development Research Centre</narrative>
    <narrative xml:lang="FR">Centre de recherches pour le d&#xE9;veloppement international</narrative>
    <narrative xml:lang="ES">Centro Internacional de Investigaciones para el Desarrollo</narrative>
   </receiver-org>
   <recipient-region vocabulary="1"></recipient-region>
   <transaction-date iso-date="2016-03-31"></transaction-date>
   <transaction-type code="2"></transaction-type>
   <value currency="CAD" value-date="2016-03-31">
   </value>
  </transaction>
  <transaction>
   <disbursement-channel code="2"></disbursement-channel>
   <provider-org>
    <narrative xml:lang="EN">Canada. Parliament</narrative>
    <narrative xml:lang="FR">Canada. Parlement</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">International Development Research Centre</narrative>
    <narrative xml:lang="FR">Centre de recherches pour le d&#xE9;veloppement international</narrative>
    <narrative xml:lang="ES">Centro Internacional de Investigaciones para el Desarrollo</narrative>
   </receiver-org>
   <recipient-region vocabulary="1"></recipient-region>
   <transaction-date iso-date="2015-03-31"></transaction-date>
   <transaction-type code="2"></transaction-type>
   <value currency="CAD" value-date="2015-03-31">
   </value>
  </transaction>
  <transaction>
   <disbursement-channel code="2"></disbursement-channel>
   <provider-org>
    <narrative xml:lang="EN">Canada. Global Affairs Canada</narrative>
    <narrative xml:lang="FR">Canada. Affaires mondiales Canada</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">International Development Research Centre</narrative>
    <narrative xml:lang="FR">Centre de recherches pour le d&#xE9;veloppement international</narrative>
    <narrative xml:lang="ES">Centro Internacional de Investigaciones para el Desarrollo</narrative>
   </receiver-org>
   <recipient-region vocabulary="1"></recipient-region>
   <transaction-date iso-date="2015-03-31"></transaction-date>
   <transaction-type code="2"></transaction-type>
   <value currency="CAD" value-date="2015-03-31">
   </value>
  </transaction>
 </iati-activity>
</iati-activities>
